_19-sean-scott-vp-amp-gm-clinical-genomics-qiagen-bioinformatics-session-cancer-dx.jpg "19. Sean Scott, VP & GM, Clinical Genomics, QIAGEN Bioinformatics- Session: Cancer Dx from ngs terms Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 9 min 17 sec
✓ Published: 16-Feb-2016
✓ Published: 16-Feb-2016
Description:
Scaling NGS Test Interpretation and Reporting In OncologynnThe interpretation and reporting of “actionable” somatic cancer variants, in terms of approved targeted therapies and the matching of patients to trials, continues to be a major rate-limiting factor for the broader adoption of NGS based panels. Sean P. Scott, VP of Clinical Market Development for QIAGEN, will highlight some of the unmet needs and challenges that clinical testing labs encounter with new NGS diagnostic tests and briefl
Scaling NGS Test Interpretation and Reporting In OncologynnThe interpretation and reporting of “actionable” somatic cancer variants, in terms of approved targeted therapies and the matching of patients to trials, continues to be a major rate-limiting factor for the broader adoption of NGS based panels. Sean P. Scott, VP of Clinical Market Development for QIAGEN, will highlight some of the unmet needs and challenges that clinical testing labs encounter with new NGS diagnostic tests and briefl
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
![[+]](/images/menu.gif){kind=small}